Gliadin (Deamidated) Antibody, IgA, Serum
Use
The test is useful for assessing deaminated gliadin IgA antibodies in patients suspected of having celiac disease. It is particularly relevant for patients with compatible clinical symptoms, atypical symptoms, or those at increased risk due to family history, existing disorders, or positivity for HLA DQ2/DQ8. Additionally, the test is used to monitor the response of celiac disease patients to a gluten-free diet, where declining antibody levels may indicate therapeutic response.
Special Instructions
Not provided.
Limitations
This test should not be used as the sole determinant for diagnosing celiac disease. It identifies candidates with increased probability for the disease who may require a small intestine biopsy. A negative result may occur if the patient has been on a gluten-free diet prior to testing. If serology is negative and symptoms persist, further investigation including endoscopy and biopsy should be considered. IgA deficiency might lead to false-negative results, necessitating measurement of total IgA. Testing for antibodies to unmodified gliadin proteins is outdated due to low accuracy.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Gliadin (Deamidated) IgA
Protein
LOINC Codes
- 47393-4 - Gliadin peptide IgA Ser Ql IA
- 47393-4 - Gliadin peptide IgA Ser Ql IA
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis; Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |